Innovative therapeutical approaches for hematological malignancies based on molecular targeted therapies

被引:2
作者
Zauli, Giorgio [1 ]
机构
[1] Univ Ferrara, Dept Morphol & Embryol, I-44100 Ferrara, Italy
关键词
D O I
10.2174/138161208785294645
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
引用
收藏
页码:2022 / 2022
页数:1
相关论文
共 7 条
[1]   Potential therapeutic applications of miRNA-based technology in hematological malignancies [J].
Barbarotto, Elisa ;
Calin, George A. .
CURRENT PHARMACEUTICAL DESIGN, 2008, 14 (21) :2040-2050
[2]   Targeting cyclooxygenase-2 in hematological malignancies: Rationale and promise [J].
Bernard, M. P. ;
Bancos, S. ;
Sime, P. J. ;
Phipps, R. P. .
CURRENT PHARMACEUTICAL DESIGN, 2008, 14 (21) :2051-2060
[3]   An update on the xenograft and mouse models suitable for investigating new therapeutic compounds for the treatment of B-cell malignancies [J].
Macor, Paolo ;
Secco, Erika ;
Zorzet, Sonia ;
Tripodo, Claudio ;
Celeghini, Claudio ;
Tedesco, Francesco .
CURRENT PHARMACEUTICAL DESIGN, 2008, 14 (21) :2023-2039
[4]   Potential role of PKC inhibitors in the treatment of hematological malignancies [J].
Mischiati, Carlo ;
Melloni, Elisabetta ;
Corallini, Federica ;
Milani, Daniela ;
Bergamini, Carlo ;
Vaccarezza, Mauro .
CURRENT PHARMACEUTICAL DESIGN, 2008, 14 (21) :2075-2084
[5]   A combined approach with rituximab plus Anti-TRAIL-R agonistic antibodies for the treatment of haematological malignancies [J].
Sancilio, Silvia ;
Grill, Vittorio ;
Di Pietro, Roberta .
CURRENT PHARMACEUTICAL DESIGN, 2008, 14 (21) :2085-2099
[6]   The MDM2 inhibitor nutlins as an innovative therapeutic tool for the treatment of haematological malignancies [J].
Secchiero, Paola ;
di Iasio, Maria Grazia ;
Gonelli, Arianna ;
Zauli, Giorgio .
CURRENT PHARMACEUTICAL DESIGN, 2008, 14 (21) :2100-2110
[7]   Anticancer alkylphospholipids: Mechanisms of action, cellular sensitivity and resistance, and clinical prospects [J].
van Blitterswijk, Wim J. ;
Verheij, Marcel .
CURRENT PHARMACEUTICAL DESIGN, 2008, 14 (21) :2061-2074